The concern of generic rivalry has long loomed around copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the prospects of connected pharmaceutical portfolios. While early times saw impressive returns, the exclusivity end has allowed the path for discounted substitutes, potentially reducing profitability and posing a real risk for